A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options (Q28704122)

2

0 references

Tae Jin Lee

3

0 references

Hyung Joon Yim

4

0 references

Jong Eun Yeon

5

0 references

Young-Suk Lim

6

0 references

Min Jeong Seo

7

0 references

Sang Hoon Ahn

8

0 references

Myung Seok Lee

Creative Commons Attribution 4.0 International

9

0 references

language of work or name

English

0 references

publication date

2013

0 references

published in

PLOS One

0 references

volume

8

0 references

issue

3

0 references

page(s)

e57900

0 references

copyright license

start time

11 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Global epidemiology of hepatitis B virus

17 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

17 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea: a multi-center, nation-wide, cross-sectional epidemiologic study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Safety evaluation of telbivudine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

The societal burden of HBV-related disease: South Korea

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Lamivudine for patients with chronic hepatitis B and advanced liver disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Outcome of liver transplantation for hepatitis B in the United States

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Epidemiology of hepatitis B virus infection in the Asia-Pacific region

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

3 June 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0057900

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0057900

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0057900

A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0057900

Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0057900

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0057900

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3863204

Health economics: an introduction for clinicians

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23536775

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23536775

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0057900

1 reference

ADS bibcode

2013PLoSO...857900P

0 references

1 reference

1 reference

PubMed publication ID

23536775

1 reference